These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 18776936)

  • 1. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.
    Agger EM; Rosenkrands I; Hansen J; Brahimi K; Vandahl BS; Aagaard C; Werninghaus K; Kirschning C; Lang R; Christensen D; Theisen M; Follmann F; Andersen P
    PLoS One; 2008 Sep; 3(9):e3116. PubMed ID: 18776936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses.
    Milicic A; Kaur R; Reyes-Sandoval A; Tang CK; Honeycutt J; Perrie Y; Hill AV
    PLoS One; 2012; 7(3):e34255. PubMed ID: 22470545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations.
    Christensen D; Foged C; Rosenkrands I; Lundberg CV; Andersen P; Agger EM; Nielsen HM
    Int J Pharm; 2010 May; 390(1):19-24. PubMed ID: 19879346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice.
    Gram GJ; Karlsson I; Agger EM; Andersen P; Fomsgaard A
    PLoS One; 2009 Sep; 4(9):e6950. PubMed ID: 19759892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
    Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
    J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary Administration of the Liposome-Based Adjuvant CAF01: Effect of Surface Charge on Mucosal Adjuvant Function.
    Müllertz OAO; Andersen P; Christensen D; Foged C; Thakur A
    Mol Pharm; 2023 Feb; 20(2):953-970. PubMed ID: 36583936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll like-receptor agonist Pam
    Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
    Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
    Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
    J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome-based cationic adjuvant formulations (CAF): past, present, and future.
    Christensen D; Agger EM; Andreasen LV; Kirby D; Andersen P; Perrie Y
    J Liposome Res; 2009; 19(1):2-11. PubMed ID: 19515003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
    Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
    Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells.
    Kamath AT; Rochat AF; Christensen D; Agger EM; Andersen P; Lambert PH; Siegrist CA
    PLoS One; 2009 Jun; 4(6):e5771. PubMed ID: 19492047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
    Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
    Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice.
    Akache B; Stark FC; Jia Y; Deschatelets L; Dudani R; Harrison BA; Agbayani G; Williams D; Jamshidi MP; Krishnan L; McCluskie MJ
    PLoS One; 2018; 13(12):e0208067. PubMed ID: 30513093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
    Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
    Front Immunol; 2020; 11():575504. PubMed ID: 33117374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocorrelates of CAF family adjuvants.
    Pedersen GK; Andersen P; Christensen D
    Semin Immunol; 2018 Oct; 39():4-13. PubMed ID: 30396811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan.
    Vono M; Eberhardt CS; Mohr E; Auderset F; Christensen D; Schmolke M; Coler R; Meinke A; Andersen P; Lambert PH; Mastelic-Gavillet B; Siegrist CA
    Front Immunol; 2018; 9():381. PubMed ID: 29541075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
    Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
    J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
    Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach.
    Rose F; Wern JE; Ingvarsson PT; van de Weert M; Andersen P; Follmann F; Foged C
    J Control Release; 2015 Jul; 210():48-57. PubMed ID: 25957906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.